Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 26, 2011

Roche to Assess Cerep's BioPrint Database and Pharmaco-Informatics Tools

  • Shire will evaluate Cerep's BioPrint database and related pharmaco-informatics tools. Under the agreement Cerep will also generate new BioPrint data on Shire compounds for Shire’s exclusive use. Additionally, the two companies will also collaborate on the development of BioPrint and related tools aimed at predicting adverse drug reactions as early as possible in preclinical research.

    BioPrint is a homogenous pharmacology and ADME database composed of three main data sets: chemical descriptors (structures and chemical information as well as 2-D and 3-D descriptors), in vitro profiles, and in vivo effects of drugs or reference compounds. It places a new drug candidate in the context of marketed drugs, anticipating potential in vivo liabilities, predicting off-target activities, and ADME characteristics.

    In October 2009, Cerep granted a similar BioPrint evaluation license to Roche spanning two years. The companies agreed to extend their contract for an additional year in October 2010. Thierry Jean, president and CEO of Cerep, says that the database is a result of 12 years of investment and work.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »